CureVac Target of Unusually High Options Trading (NASDAQ:CVAC)

CureVac (NASDAQ:CVAC) was the recipient of some unusual options trading on Thursday. Investors purchased 1,936 call options on the company. This represents an increase of approximately 849% compared to the average daily volume of 204 call options.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Greenleaf Trust purchased a new stake in CureVac during the 1st quarter worth about $31,000. Integrated Wealth Concepts LLC lifted its holdings in CureVac by 25.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company’s stock worth $42,000 after purchasing an additional 3,000 shares in the last quarter. Two Sigma Advisers LP purchased a new stake in CureVac during the 4th quarter worth about $48,000. Jump Financial LLC purchased a new stake in CureVac during the 4th quarter worth about $55,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in CureVac during the 4th quarter worth about $66,000. Institutional investors own 17.26% of the company’s stock.

CureVac Stock Down 0.5%

CVAC stock opened at $5.57 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The company has a market capitalization of $1.25 billion, a price-to-earnings ratio of 10.13 and a beta of 2.49. CureVac has a fifty-two week low of $2.37 and a fifty-two week high of $5.72. The stock has a fifty day moving average of $3.76 and a 200-day moving average of $3.48.

CureVac (NASDAQ:CVAC) last posted its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.08). The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. As a group, equities research analysts predict that CureVac will post 0.72 earnings per share for the current year.

Analysts Set New Price Targets

CVAC has been the subject of a number of recent analyst reports. UBS Group reduced their price objective on CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, April 30th. JMP Securities restated a “market outperform” rating and issued a $10.00 price objective on shares of CureVac in a research note on Wednesday, May 28th. Finally, Jefferies Financial Group restated a “hold” rating and issued a $5.00 price objective (down previously from $7.00) on shares of CureVac in a research note on Friday.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.